argenx N.V. is having to take a gradual approach to growing Vyvgart sales as the generalized myasthenia gravis (gMG) product faces hurdles from the COVID-19 pandemic and the lack of medical education on the drug’s target, FcRn.
The US Food and Drug Administration gave Vyvgart (efgartigimod alfa-fcab) the green light on 17 December on the back of...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
